A Review on Generic and Branded Drugs-Competence of Generic Drugs in Comparison to Branded Drugs

Kunal Arora; Sumita Singh; Pranjal Kumar Singh

doi:10.24092/CRPS.2019.090402

Kunal Arora Department of Pharmaceutics, Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Sumita Singh Department of Pharmaceutics, Kharvel Subharti College of Pharmacy, Swami Vivekanand Subharti University, Meerut, Uttar Pradesh, India
Pranjal Kumar Singh Department of Pharmaceutics, Dr. K.N. Modi Institute of Pharmaceutical Education and Research, Modinagar, Uttar Pradesh, India

DOI https://doi.org/10.24092/CRPS.2019.090402

Abstract

The use of generic or branded drug is a great matter of discussion in recent times globally. The government in different countries is also strictly promoting the use of generic drugs in place of branded ones. A generic drug consists of same active ingredient/ingredients as its branded counterpart and found to be equally efficient therapeutically. The cost of generic drugs are much lesser than the branded drugs as they do not need to go through the robust and costly pre-clinical or clinical studies as done in branded ones which increases the cost of them up to many folds. The present review enlightens the effectiveness of generic drugs as compared to branded drugs and how they work in body. An attempt is also made to highlight the cost comparison between both classes, the regulations and control pertaining to generic and branded drugs.

Keywords: Generic Drugs, Branded Drugs, Rational use of Generics as compared to Branded drugs

References

1. Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT. Comparing generic and innovator drugs: A review of 12 y of bioequivalence data from the United States food and drug administration. Annals ofPharmacotherapy. 2009;43:1583-97.
2. Arafat Mosab, Ahmed Zahaa, Arafat Osama. Comparison between generic drugs and brand name drugs from bioequivalence andthermoequivalence prospective. InternationalJournal of Pharmacy and Pharmaceutical Sciences.2017; 9(6): 1-4.
3. FDA Fact sheet: What’s involved in reviewing and approving generic drugs applications? Available from: https: www. fda. gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm506040 accessed on 10/12/19.
4. Moore N, Berdai D, Begaud B. Are generic drugs really inferior medicines? Clinical Pharmacology and Therapeutics.2010;88(4):302-304.
5. Wilner AN. Therapeutic equivalency of generic antiepileptic drugs: Results of a survey. Epilepsy and Behavior.2004;5(1): 995-998.
6. Qumbar M. DOE based stability indicating RP-HPLC method for determination of lacidipine in niosomal gel in rat: Pharmacokinetic Determination. PharmaceuticaAnalytica Acta.2014; 5:314-317.
7. Sanaa A. Awareness and perception of national pharmacovigilance center among lebanese medical staff. Journal ofPharmacovigilance. 2016;4(1):1-5.
8. https://www. verywellhealth. com/generic-drug-safety-and-effectiveness-1738890 accessed on 12/12/19.
9. Dentali F, Donadini MP, Clark N, Crowther MA, Garcia D, Hylek E. Brand name versus generic warfarin: A systematic review of the literature. Pharmacotherapy Journal.2011;31(3):86-93.
10. www. pradhanmantrijanaushdi. com accessed on 12/12/19.
11. www. medindia. netaccessed on 12/12/19.
12. www. indiamart. comaccessed on 12/12/19.
13. SingalGL,NandaArun,Kotwani Anita. A comparative evaluation of price and quality of some branded versus branded–generic medicines of the same manufacturer in India. Indian Journal Of Pharmacology.2011; 43(2):131-136.
14. Stegemann S, Klebovich I, Antal I, Blume HH, Magyar K, Nemeth G. Improved therapeutic entities derived from known generics as an unexplored source of innovative drug products. European Journal of Pharmaceutical Scinces.2011;44(2):447-454.
15. Moore N, Berdai D, Begaud B. Are generic drugs really inferior medicines? Clinical Pharmacology and Therapeutics.2010;88:302-304.
16. Swain Suryakanta, DeyAnkita, PatraChinamNiranjan, EswaraMuddana, RaoBhanoji.Pharmaceutical regulations for generic drug products in India and US. Case Studies and Future Prospectives.2015;3(2):1-6.